Get the Daily Brief
Latest Biotech News
Korsana raises $175M to push brain‑penetrant Alzheimer’s antibodies
Korsana Biosciences disclosed a $175 million financing to advance a platform engineered to ferry antibodies across the blood‑brain barrier for Alzheimer’s disease and other neurologic indications....
Illuminare’s fluorescent nerve agent clears Phase 1 – surgery visualization advances
Illuminare Biotechnologies reported first‑in‑human Phase 1 data showing Illuminare‑1, a fluorescent agent that binds myelin, enables rapid and sustained intraoperative nerve visualization under...
MoonLake posts mid‑stage arthritis win ahead of FDA filing
MoonLake Immunotherapeutics reported Phase 2 results showing its investigational drug produced clinically meaningful benefit in patients with an aggressive inflammatory arthritis subtype, a...
Altesa raises $75M series B led by former official Giroir
Altesa secured a $75 million Series B to advance an antiviral program, with former HHS official Brett Giroir reported as a lead investor in the financing, according to BioCentury’s finance report....
Japan backs two iPSC therapies under conditional approval pathway
Japan’s regulators endorsed conditional approvals for two induced pluripotent stem cell (iPSC)‑derived therapies—Amchepry (raguneprocel) from Sumitomo/Racthera and Reheart (Cuorips)—paving the way...
Bioversys reports clinical proof‑of‑concept for TB combo in NEJM
Bioversys published Phase IIa early bactericidal activity data for alpibectir (BVL‑GSK098) combined with ethionamide in pulmonary tuberculosis in the New England Journal of Medicine, reporting the...
Messy LNPs deliver better: new data reshapes mRNA delivery assumptions
Two independent reports presented converging evidence that structural heterogeneity in lipid nanoparticles (LNPs) can improve intracellular cargo release. University of Copenhagen researchers used...
Bacterial RNR control unraveled – new target class for antimicrobials
Structural and mechanistic studies revealed how bacteria regulate ribonucleotide reductases (RNRs) via the transcriptional regulator NrdR, clarifying nucleotide sensing and transcriptional control...
Korsana raises $175M: Funds brain‑penetrant Alzheimer's antibody push
Korsana Biosciences announced a $175 million financing to advance antibody therapeutics engineered to cross the blood‑brain barrier for Alzheimer’s disease. The startup’s preclinical program uses...
Illuminare-1 lights nerves: Phase 1 shows rapid, sustained surgical visualization
Illuminare Biotechnologies reported first‑in‑human Phase 1 results for Illuminare‑1, an imaging agent that binds myelin and fluoresces under blue light to reveal peripheral nerves during surgery....
FDA resets course on Moderna flu vaccine: Agency will review application
The FDA reversed an earlier refusal‑to‑file decision and agreed to review Moderna’s seasonal mRNA flu vaccine mRNA‑1010, setting a PDUFA target of Aug. 5. Moderna said the agency accepted a...
Grail’s Galleri misses primary endpoint – shares crater
Grail reported that its large NHS‑Galleri multicancer screening trial did not meet the primary endpoint of a statistically significant reduction in late‑stage (III–IV) combined cancer diagnoses....
Guardant acquires MetaSight: Shield screening business set to scale
Guardant Health acquired early cancer‑detection startup MetaSight Diagnostics for $59 million upfront plus up to $90 million in contingent payments, expanding its screening portfolio alongside its...
Ionis halts Alzheimer’s program for people with Down syndrome
Ionis Pharmaceuticals ended development of an Alzheimer’s drug candidate aimed at people with Down syndrome, the company confirmed to Endpoints News. The discontinuation removes a targeted effort...
Japan endorses two iPSC drugs: Regulatory first for cell‑derived therapies
Japan’s regulatory advisory committee recommended conditional approvals for two induced pluripotent stem cell (iPSC)‑derived therapies—Amchepry (raguneprocel) and Reheart—under the country’s...
Insilico and Lilly map 'prompt‑to‑drug' autonomous R&D
Researchers from Insilico Medicine and Eli Lilly published a vision in ACS Central Science outlining a fully autonomous, AI‑driven 'prompt‑to‑drug' pipeline that integrates generative models...
Novartis to sell India unit – keeps R&D and commercial operations
Novartis said it will sell its 70.68% stake in Novartis India Limited to a consortium of private equity firms for about $159 million, while retaining Novartis Healthcare Private Limited, its...
Bioversys reports TB proof‑of‑concept in NEJM: Alpibectir potentiates ethionamide
Bioversys published phase IIa early bactericidal activity data in the New England Journal of Medicine showing that alpibectir (BVL‑GSK098) combined with ethionamide demonstrated clinical...
Grail’s Galleri misses NHS endpoint – shares plunge
The National Health Service trial of Grail’s Galleri multicancer early detection (MCED) test failed to meet its primary endpoint of a statistically significant reduction in stage III–IV cancers....
FDA reopens review of Moderna’s mRNA flu shot – political pressure scrutinized
The FDA reversed an earlier refusal-to-file and agreed to review Moderna’s seasonal mRNA flu vaccine mRNA-1010 after a Type A meeting with the company, setting a PDUFA-style target decision date...